Patients with wAIHA were identified based on a diagnosis code of “autoimmune hemolytic anemia” (AIHA), chronic use of steroids (≥30 days) in the last 36 months, and chronic use of non-steroidal ...
Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, ...